Publications by authors named "Marten Heeringa"

Claim this Profile
S
Safety and Immunogenicity of Cell-Based Quadrivalent Influenza Vaccine: A Randomized Trial.
Brandon J Essink, Marten Heeringa, Robert J Jeanfreau, Daniel Finn, Vince Matassa

Pediatrics· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of a Cell-Culture-Derived Quadrivalent Influenza Vaccine in Children.
Terence Nolan, Alexandre C Fortanier, Brett Leav, Airi Põder, Lulu C Bravo, Marten Heeringa

N Engl J Med· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparability of Titers of Antibodies against Seasonal Influenza Virus Strains as Determined by Hemagglutination Inhibition and Microneutralization Assays.
Marten Heeringa, Brett Leav, Igor Smolenov, Giuseppe Palladino, Leah Isakov

J Clin Microbiol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study.
Yohann Loriot, Karim Fizazi, Robert J Jones, Jan Van den Brande, Rhoda L Molife, Marten Heeringa

Invest New Drugs· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro and in vivo characterisation of ASP9521: a novel, selective, orally bioavailable inhibitor of 17β-hydroxysteroid dehydrogenase type 5 (17βHSD5; AKR1C3).
Aya Kikuchi, Takashi Furutani, Hidenori Azami, Kazushi Watanabe, Tatsuya Niimi, Marten Heeringa

Invest New Drugs· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The pharmacokinetics of darexaban (YM150), an oral direct factor Xa inhibitor, are not affected by ketoconazole, a strong inhibitor of CYP3A and P-glycoprotein.
Dorien Groenendaal, Gregory Strabach, Alberto Garcia-Hernandez, Takeshi Kadokura, Marten Heeringa

Clin Pharmacol Drug Dev· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Darexaban (YM150), an oral direct factor Xa inhibitor, has no effect on the pharmacokinetics of digoxin.
Takeshi Kadokura, Dorien Groenendaal, Marten Heeringa, Roelof Mol, Frank Verheggen

Eur J Drug Metab Pharmacokinet· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical pharmacokinetics, pharmacodynamics, safety and tolerability of darexaban, an oral direct factor Xa inhibitor, in healthy Caucasian and Japanese subjects.
Takeshi Kadokura, Makoto Kashiwa, Dorien Groenendaal, Marten Heeringa, Roelof Mol

Biopharm Drug Dispos· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Absorption, metabolism and excretion of darexaban (YM150), a new direct factor Xa inhibitor in humans.
Tadashi Hashimoto, Katsuhiro Suzuki, Yukie Kihara, Takafumi Iwatsubo, Aiji Miyashita, Marten Heeringa

Xenobiotica· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The pharmacokinetics of darexaban are not affected to a clinically relevant degree by rifampicin, a strong inducer of P-glycoprotein and CYP3A4.
Dorien Groenendaal, Gregory Strabach, Alberto Garcia-Hernandez, Takeshi Kadokura, Marten Heeringa

Br J Clin Pharmacol· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum biomarkers in nonalcoholic steatohepatitis: value for assessing drug effects?
Marten Heeringa, Ann Hastings, Shunji Yamazaki, Paul de Koning

Biomark Med· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, dose-response study of sugammadex given for the reversal of deep rocuronium- or vecuronium-induced neuromuscular blockade under sevoflurane anesthesia.
Philippe Duvaldestin, Karel Kuizenga, Vera Saldien, Casper Claudius, Frédérique Servin, Marten Heeringa

Anesth Analg· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reversal of neuromuscular blockade by sugammadex after continuous infusion of rocuronium in patients randomized to sevoflurane or propofol maintenance anesthesia.
Christopher Rex, Stefanie Wagner, Claudia Spies, Jens Scholz, Henk Rietbergen, Marten Heeringa

Anesthesiology· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reversal of rocuronium-induced (1.2 mg/kg) profound neuromuscular block by sugammadex: a multicenter, dose-finding and safety study.
Hans D de Boer, Jacques J Driessen, Marco A E Marcus, Hans Kerkkamp, Marten Heeringa

Anesthesiology· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effective reversal of moderate rocuronium- or vecuronium-induced neuromuscular block with sugammadex, a selective relaxant binding agent.
Koen Suy, Karl Morias, Guy Cammu, Pol Hans, Wilbert G F van Duijnhoven, Marten Heeringa

Anesthesiology· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis